Later studies demonstrated that there was no clear benefit of IL-2 addition to the regimen, and thus, it was omitted and is not included in current protocols.69 A second anti-GD2 mAb, naxitamab, which combined with GM-CSF, is used for the treatment of high-risk NB patients with relapsed or refractory disease limited to the bone or bone marrow.142. This evidence concerns the gene IL2 and neuroblastoma.